{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:21:53Z","timestamp":1778916113003,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12072-019-09932-9","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T18:20:48Z","timestamp":1549650048000},"page":"234-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Influence of proton pump inhibitors on microbiota in chronic liver disease patients"],"prefix":"10.1007","volume":"13","author":[{"given":"Kenta","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiji","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"9932_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2016.09.007","volume":"152","author":"C-F Tsai","year":"2017","unstructured":"Tsai C-F, Chen M-H, Wang Y-P, Chu C-J, Huang Y-H, Lin H-C, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology. 2017;152:134\u2013141 (W.B. Saunders)","journal-title":"Gastroenterology"},{"key":"9932_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.dld.2015.12.009","volume":"48","author":"T Yu","year":"2016","unstructured":"Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis. Dig Liver Dis. 2016;48:353\u2013359 (W.B. Saunders)","journal-title":"Dig Liver Dis"},{"key":"9932_CR3","first-page":"8195","volume":"8566","author":"Y Naito","year":"2018","unstructured":"Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal dysbiosis secondary to proton-pump inhibitor use. Digestion. 2018;8566:8195\u20138204","journal-title":"Digestion"},{"key":"9932_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11894-017-0577-6","volume":"19","author":"A Minalyan","year":"2017","unstructured":"Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep. 2017;19:42","journal-title":"Curr Gastroenterol Rep"},{"key":"9932_CR5","first-page":"249","volume":"5","author":"H Fukui","year":"2017","unstructured":"Fukui H. Gut microbiome-based therapeutics in liver cirrhosis: basic consideration for the next step. J Clin Transl Hepatol. 2017;5:249\u2013260 (Xia & He Publishing Inc. (USA))","journal-title":"J Clin Transl Hepatol"},{"key":"9932_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0085-9","author":"JS Bajaj","year":"2018","unstructured":"Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am J Gastroenterol. 2018. \n                    https:\/\/doi.org\/10.1038\/s41395-018-0085-9\n                    \n                  \n                           (Nature Publishing Group)","journal-title":"Am J Gastroenterol"},{"key":"9932_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0962280210394483","volume":"21","author":"E Williamson","year":"2012","unstructured":"Williamson E, Morley R, Lucas A, Carpenter J. Propensity scores: from na\u00efve enthusiasm to intuitive understanding. Stat Methods Med Res. 2012;21:273\u2013293 (SAGE Publications, London)","journal-title":"Stat Methods Med Res"},{"key":"9932_CR8","doi-asserted-by":"publisher","first-page":"G951","DOI":"10.1152\/ajpgi.00268.2014","volume":"307","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. AJP Gastrointest Liver Physiol. 2014;307:G951\u2013G957 (American Physiological Society)","journal-title":"AJP Gastrointest Liver Physiol"},{"key":"9932_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749\u2013756 (BMJ Publishing Group)","journal-title":"Gut"},{"key":"9932_CR10","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1038\/ctg.2015.20","volume":"6","author":"A Tsuda","year":"2015","unstructured":"Tsuda A, Suda W, Morita H, Takanashi K, Takagi A, Koga Y, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol. 2015;6:e89 (Nature Publishing Group)","journal-title":"Clin Transl Gastroenterol"},{"key":"9932_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/hep.28737","volume":"64","author":"G Dam","year":"2016","unstructured":"Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64:1265\u20131272","journal-title":"Hepatology"},{"key":"9932_CR12","doi-asserted-by":"publisher","first-page":"e6723","DOI":"10.1097\/MD.0000000000006723","volume":"96","author":"J Bian","year":"2017","unstructured":"Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, et al. Association between proton pump inhibitors and hepatic encephalopathy: a meta-analysis. Medicine (Baltimore). 2017;96:e6723","journal-title":"Medicine (Baltimore)"},{"key":"9932_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/jgh.12065","volume":"28","author":"A Deshpande","year":"2013","unstructured":"Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28:235\u2013242","journal-title":"J Gastroenterol Hepatol"},{"key":"9932_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","volume":"53","author":"T Su","year":"2018","unstructured":"Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53:27\u201336 (Springer, Japan)","journal-title":"J Gastroenterol"},{"key":"9932_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12876-016-0484-6","volume":"16","author":"EJ Giamarellos-Bourboulis","year":"2016","unstructured":"Giamarellos-Bourboulis EJ, Pyleris E, Barbatzas C, Pistiki A, Pimentel M. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 2016;16:67","journal-title":"BMC Gastroenterol"},{"key":"9932_CR16","first-page":"268","volume":"62","author":"Y Fujiwara","year":"2015","unstructured":"Fujiwara Y, Watanabe T, Muraki M, Yamagami H, Tanigawa T, Shiba M, et al. Association between chronic use of proton pump inhibitors and small-intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests. Hepatogastroenterology. 2015;62:268\u2013272","journal-title":"Hepatogastroenterology"},{"key":"9932_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740\u2013748 (BMJ Publishing Group)","journal-title":"Gut"},{"key":"9932_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1136\/gutjnl-2016-313312","volume":"66","author":"T Otsuka","year":"2017","unstructured":"Otsuka T, Sugimoto M, Inoue R, Ohno M, Ban H, Nishida A, et al. Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut. 2017;66:1723\u20131725 (BMJ Publishing Group)","journal-title":"Gut"},{"key":"9932_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","volume":"54","author":"Y Chen","year":"2011","unstructured":"Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562\u2013572 (Wiley Subscription Services, Inc., A Wiley Company)","journal-title":"Hepatology."},{"key":"9932_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cid\/ciy205","volume":"67","author":"T Inoue","year":"2018","unstructured":"Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, et al. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis. 2018;67:869\u2013877","journal-title":"Clin Infect Dis"},{"key":"9932_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1472-765X.2007.02129.x","volume":"44","author":"SH Duncan","year":"2007","unstructured":"Duncan SH, Louis P, Flint HJ. Cultivable bacterial diversity from the human colon. Lett Appl Microbiol. 2007;44:343\u2013350 (Wiley\/Blackwell (10.1111))","journal-title":"Lett Appl Microbiol."},{"key":"9932_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.chom.2015.03.006","volume":"17","author":"V Leone","year":"2015","unstructured":"Leone V, Gibbons SM, Martinez K, Hutchison AL, Huang EY, Cham CM, et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism. Cell Host Microbe. 2015;17:681\u2013689 (NIH Public Access)","journal-title":"Cell Host Microbe"},{"key":"9932_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","volume":"58","author":"G Kakiyama","year":"2013","unstructured":"Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58:949\u2013955 (NIH Public Access)","journal-title":"J Hepatol"},{"key":"9932_CR24","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/ajg.2013.221","volume":"108","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 2013;108:1601\u20131611 (Nature Publishing Group)","journal-title":"Am J Gastroenterol"},{"key":"9932_CR25","doi-asserted-by":"publisher","first-page":"26800","DOI":"10.1038\/srep26800","volume":"6","author":"V Ahluwalia","year":"2016","unstructured":"Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, et al. Impaired gut-liver-brain axis in patients with cirrhosis. Sci Rep. 2016;6:26800 (Nature Publishing Group)","journal-title":"Sci Rep"},{"key":"9932_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4161\/gmic.28684","volume":"5","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS. The role of microbiota in hepatic encephalopathy. Gut Microbes. 2014;5:397\u2013403 (Taylor and Francis)","journal-title":"Gut Microbes"},{"key":"9932_CR27","doi-asserted-by":"publisher","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","volume":"302","author":"JS Bajaj","year":"2012","unstructured":"Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302:G168\u2013G175 (American Physiological Society)","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"9932_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3164\/jcbn.17-78","volume":"62","author":"T Takagi","year":"2018","unstructured":"Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62:100\u2013105 (The Society for Free Radical Research Japan)","journal-title":"J Clin Biochem Nutr"},{"key":"9932_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-016-0009-6","volume":"8","author":"C Llorente","year":"2017","unstructured":"Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017;8:1\u201314 (Springer, US)","journal-title":"Nat Commun"},{"key":"9932_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59\u201364 (Nature Publishing Group)","journal-title":"Nature"},{"key":"9932_CR31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","volume":"60","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. The cirrhosis dysbiosis ratio defines changes in the gut microbiome associated with cirrhosis and its complications. J Hepatol. 2014;60:940\u2013947 (NIH Public Access)","journal-title":"J Hepatol"},{"key":"9932_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13099-016-0124-2","volume":"8","author":"AM Aly","year":"2016","unstructured":"Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog. 2016;8:42 (BioMed Central)","journal-title":"Gut Pathog"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-019-09932-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09932-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09932-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T19:23:52Z","timestamp":1581103432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-019-09932-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["9932"],"URL":"https:\/\/doi.org\/10.1007\/s12072-019-09932-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"assertion":[{"value":"12 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the Research Ethics Committee of Nagoya University Hospital on August 30, 2016 (Protocol number 2015-0420). In accordance with the Declaration of Helsinki, written informed consent was obtained from all patients before registration. This study is registered in University Hospital Medical Information Network Clinical Trials Registry (UMIN ID: 000020269).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}